Mov­ing on from a tri­al dis­as­ter, Juno re­ports pos­i­tive da­ta for JCAR017 -- and a death

Look­ing to dis­tance it­self from a tri­al dis­as­ter that claimed 5 lives last year, Juno Ther­a­peu­tics $JUNO to­day turned to a batch of pos­i­tive ear­ly-stage non-Hodgkin lym­phoma da­ta on its new lead CAR-T ther­a­py, JCAR017.

In­ves­ti­ga­tors for the biotech say that they have gath­ered da­ta that demon­strate its promise, out­lin­ing a com­bined over­all re­sponse rate of 86% and a com­plete re­sponse rate of 59% — 26 out of 44 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER